Related Experiment Videos
[Critical analysis of beta blockers in heart failure: certainty and incompleteness]
1Istituto di Cardiologia, Università degli Studi, Bologna. crapezzi@orsola-malpighi.med.unibo.it
Insights
Beta-blockers significantly improve outcomes for patients with chronic heart failure, reducing mortality and improving ventricular function. This therapy offers a life saved for every 35 patients treated in mild-to-moderate cases.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Heart failure is a leading cause of disability in industrialized nations.
- Beta-blocker efficacy in heart failure was long debated.
Purpose:
- To review the evidence for beta-blocker use in chronic heart failure.
- To highlight the benefits and remaining questions regarding beta-blocker therapy.
Summary:
- Recent trials confirm beta-blockers improve ventricular function, clinical status, morbidity, and mortality in chronic heart failure.
- Therapy can save one life per 35 patients with mild-to-moderate heart failure.
- Beta-blockers positively impact cardiac remodeling, reduce myocardial oxygen demand, and improve cardiomyocyte function.
Impact:
- Beta-blocker therapy is crucial for managing chronic heart failure.
- Further research is needed for severe heart failure, asymptomatic dysfunction, and specific patient groups.
- Understanding the precise mechanisms and class-specific effects remains an active area of investigation.
Abstract:
Heart failure is one of the commonest debilitating conditions of industrialized society, with mortality and morbidity comparable with that of the common neoplastic diseases. The role of beta-blockers in heart failure has been the subject of debate for many years. The results of recent prospective, placebo-controlled studies of the addition of beta-blockers to standard therapy in patients with chronic heart failure have confirmed a significant beneficial effect on ventricular function, clinical status, morbidity and mortality. The importance of these trials suggests that beta-adrenergic blocker therapy can save one life out of every 35 patients treated with mild-to-moderate heart failure. These major trials have used one of four beta-blockers (metoprolol, bisoprolol, carvedilol, or bucindolol) in varying study designs with different patient populations. Beta-blockers improve function of the failing left ventricle, prevent or reverse progressive left ventricular dilation, chamber sphericity, and hypertrophy, and consequently have a positive impact on cardiac remodeling. Beta-blockers also reduce heart rate and left ventricular wall stress, leading to reduced myocardial oxygen consumption, a clear benefit to the failing heart. Moreover, beta-blockers can improve the intrinsic contractile function of cardiomyocytes and have been shown to improve myocardial energetics in heart failure, possibly through desirable changes in substrate utilization. Many important clinical questions still remain unanswered. These questions include whether beta-blockers are of benefit in patients with severe NYHA functional class (IIIB-IV), in patients with asymptomatic left ventricular dysfunction, in the extreme elderly, in patients with diabetes mellitus and renal impairment. Furthermore, it is not clear whether beta-blockade by itself is the real mechanism of clinical benefit. Although certain effects of beta-blockers may be considered class effects, it is not yet clear whether there are differences between beta 1-selective antagonists and nonselective agents. Major studies are currently being undertaken to address the above questions.